Kerendia

Finerenone, the active ingredient in Kerendia, is a mineralocorticoid receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of chronic kidney disease associated with type 2 diabetes, helping to reduce renal inflammation and fibrosis.

GNH USA supplies Kerendia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Kerendia, a mineralocorticoid receptor antagonist, is used in conditions related to chronic kidney disease and diabetes.

- Chronic kidney disease associated with type 2 diabetes: slows progression of renal function decline and reduces albuminuria. - Albuminuric diabetic kidney disease: decreases urinary albumin excretion, supporting kidney health. - Cardiovascular risk in CKD with type 2 diabetes: may lower the incidence of major adverse cardiovascular events.

Finerenone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hyperkalaemia: elevated serum potassium levels. - Dizziness or light‑headedness. - Nausea or gastrointestinal discomfort. - Headache.

Serious or Rare Side Effects: - Severe hyperkalaemia leading to cardiac arrhythmia. - Acute kidney injury or worsening renal function. - Significant hypotension. - Allergic reactions such as rash or angioedema. - Hepatic injury indicated by abnormal liver enzymes.

Finerenone requires careful monitoring and specific safety measures.

- Monitor serum potassium: check levels regularly to detect hyperkalaemia. - Assess renal function: evaluate eGFR before initiation and during therapy. - Adjust dose in severe renal impairment: consider reduced dosing or avoid use. - Avoid concomitant potassium‑sparing agents: limit risk of excessive potassium. - Use with caution in pregnancy: safety category unknown, weigh benefits against risks. - Store at below 25°C: keep in the original pack, protect from moisture.

Finerenone can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalaemia. - ACE inhibitors or ARBs: increase risk of elevated potassium and renal impairment. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise finerenone plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can affect renal function. - Thiazide diuretics: may alter electrolyte balance. - Heparin: may potentiate hyperkalaemia. - Other renin‑angiotensin system agents: require close laboratory monitoring.